With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antitumor mRNA-based vaccines show potential against gastric cancer metastasis

2.

How 7,000 steps a day could help reduce your risk of cancer

3.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

4.

Study reveals crucial gaps in oral cancer awareness in Middle East and North Africa

5.

Never in a million years did I think I'd have to limit my chemotherapy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot